| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1007836391 |
| P356 | DOI | 10.1186/1475-2875-5-122 |
| P932 | PMC publication ID | 1716173 |
| P698 | PubMed publication ID | 17169157 |
| P5875 | ResearchGate publication ID | 6631166 |
| P50 | author | Grant Dorsey | Q60029509 |
| Philip J Rosenthal | Q60060211 | ||
| Bryan Greenhouse | Q37383090 | ||
| P2093 | author name string | William J Collins | |
| P2860 | cites work | Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy | Q38880633 |
| Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. | Q38883375 | ||
| An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). | Q39229078 | ||
| Molecular genotyping to distinguish between recrudescents and new infections in treatment trials of Plasmodium falciparum malaria conducted in Sub-Saharan Africa: adjustment of parasitological outcomes and assessment of genotyping effectiveness | Q39278723 | ||
| Plasmodium falciparum genotyping by microsatellites as a method to distinguish between recrudescent and new infections | Q39312870 | ||
| The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment | Q39474503 | ||
| Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children | Q40317494 | ||
| A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria | Q40503414 | ||
| Pyrimethamine and Proguanil Resistance-Conferring Mutations in Plasmodium falciparum Dihydrofolate Reductase: Polymerase Chain Reaction Methods for Surveillance in Africa | Q41933010 | ||
| Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study | Q43951050 | ||
| Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria | Q45105266 | ||
| Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand | Q47843085 | ||
| Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison | Q48031726 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eukaryote | Q19088 |
| Plasmodium falciparum | Q311383 | ||
| antimalarial | Q521616 | ||
| systematic review | Q1504425 | ||
| Plasmodium falciparum malaria | Q18554672 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 122 | |
| P577 | publication date | 2006-12-14 | |
| P1433 | published in | Malaria Journal | Q15749954 |
| P1476 | title | The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005 | |
| P478 | volume | 5 |
| Q36976565 | A general SNP-based molecular barcode for Plasmodium falciparum identification and tracking |
| Q28082023 | Advances in genetics and genomics: use and limitations in achieving malaria elimination goals |
| Q60044484 | Characterization of Plasmodium falciparum structure in Nigeria with malaria SNPs barcode |
| Q34633251 | Comparative population structure of Plasmodium malariae and Plasmodium falciparum under different transmission settings in Malawi |
| Q91660770 | Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis |
| Q39365377 | Diagnosis and genotyping of Plasmodium falciparum by a DNA biosensor based on quartz crystal microbalance (QCM). |
| Q36855449 | Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children |
| Q36561097 | Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treatment of uncomplicated malaria in adult in Senegal: open randomized trial |
| Q36146216 | Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial |
| Q37315145 | Evaluation of parasite subpopulations and genetic diversity of the msp1, msp2 and glurp genes during and following artesunate monotherapy treatment of Plasmodium falciparum malaria in Western Cambodia |
| Q38873068 | Gel versus capillary electrophoresis genotyping for categorizing treatment outcomes in two anti-malarial trials in Uganda |
| Q33590165 | Genetic diversity among Plasmodium falciparum field isolates in Pakistan measured with PCR genotyping of the merozoite surface protein 1 and 2. |
| Q41868814 | Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials |
| Q34538134 | Long term persistence of clonal malaria parasite Plasmodium falciparum lineages in the Colombian Pacific region |
| Q35071899 | Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance |
| Q24649683 | Polymerase chain reaction adjustment in antimalarial trials: molecular malarkey? |
| Q48019571 | Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. |
| Q33385477 | Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria |
| Q36691877 | Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria |
| Q37184291 | The effect of varying analytical methods on estimates of anti-malarial clinical efficacy |
| Q24615919 | The perils of PCR: can we accurately 'correct' antimalarial trials? |
| Q36489791 | Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Benin |
| Q50052786 | Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape |
| Q28391984 | Uncertain outcomes: adjusting for misclassification in antimalarial efficacy studies |
| Q36037701 | World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs |
Search more.